JP2016539096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539096A5 JP2016539096A5 JP2016524116A JP2016524116A JP2016539096A5 JP 2016539096 A5 JP2016539096 A5 JP 2016539096A5 JP 2016524116 A JP2016524116 A JP 2016524116A JP 2016524116 A JP2016524116 A JP 2016524116A JP 2016539096 A5 JP2016539096 A5 JP 2016539096A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- vegf
- composition according
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892601P | 2013-10-18 | 2013-10-18 | |
| US61/892,601 | 2013-10-18 | ||
| US201361901596P | 2013-11-08 | 2013-11-08 | |
| US61/901,596 | 2013-11-08 | ||
| US201461952923P | 2014-03-14 | 2014-03-14 | |
| US61/952,923 | 2014-03-14 | ||
| US201462055734P | 2014-09-26 | 2014-09-26 | |
| US62/055,734 | 2014-09-26 | ||
| PCT/US2014/061071 WO2015058048A1 (en) | 2013-10-18 | 2014-10-17 | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539096A JP2016539096A (ja) | 2016-12-15 |
| JP2016539096A5 true JP2016539096A5 (enExample) | 2017-11-09 |
| JP6607850B2 JP6607850B2 (ja) | 2019-11-20 |
Family
ID=51844874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524116A Active JP6607850B2 (ja) | 2013-10-18 | 2014-10-17 | Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9968674B2 (enExample) |
| EP (1) | EP3057990B1 (enExample) |
| JP (1) | JP6607850B2 (enExample) |
| KR (1) | KR102338453B1 (enExample) |
| CN (1) | CN105636986B (enExample) |
| AU (1) | AU2014337135B2 (enExample) |
| CA (1) | CA2926853C (enExample) |
| EA (1) | EA037890B1 (enExample) |
| IL (1) | IL244599B (enExample) |
| MX (1) | MX377714B (enExample) |
| WO (1) | WO2015058048A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| ES2822551T3 (es) | 2014-03-17 | 2021-05-04 | Adverum Biotechnologies Inc | Composiciones y métodos para la expresión génica mejorada en células de los conos |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| FI3265178T3 (fi) | 2015-03-02 | 2026-08-03 | Adverum Biotechnologies Inc | Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2017106462A1 (en) * | 2015-12-18 | 2017-06-22 | Biogen Ma Inc. | Bispecific antibody platform |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| MA44483A (fr) | 2016-03-24 | 2019-01-30 | Millennium Pharm Inc | Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CN117531025A (zh) | 2016-06-16 | 2024-02-09 | 阿德夫拉姆生物技术股份有限公司 | 使用aav2变体和阿柏西普治疗amd |
| SG10201912556VA (en) | 2016-07-20 | 2020-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| WO2018144587A1 (en) * | 2017-01-31 | 2018-08-09 | Research Development Foundation | Steap2 inhibitors for the treatment of liver cancers |
| WO2019099921A2 (en) | 2017-11-17 | 2019-05-23 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| SG11202007018QA (en) * | 2018-02-02 | 2020-08-28 | Oncoimmune Inc | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| KR102834864B1 (ko) * | 2018-02-02 | 2025-07-16 | 온코씨4, 아이앤씨. | 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체 |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| SG11202010589YA (en) | 2018-05-14 | 2020-11-27 | Oncoimmune Inc | Anti-cd24 compositions and uses thereof |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF |
| MX2021005048A (es) * | 2018-10-31 | 2021-09-08 | Bioatla Inc | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. |
| CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
| MX2021008983A (es) * | 2019-01-30 | 2021-09-08 | Amgen Inc | Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos. |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2026119201A1 (zh) * | 2024-12-03 | 2026-06-11 | 甘李药业股份有限公司 | 药物组合物及其用途和药盒 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19802753A1 (de) | 1998-01-26 | 1999-07-29 | Merck Patent Gmbh | Coreaktive Trägermaterialien zur Heterogenisierung von Katalysatoren, Cokatalysatoren und Liganden |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7303746B2 (en) * | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| AU2005300315A1 (en) * | 2004-11-04 | 2006-05-11 | Pfizer Products Inc. | CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
-
2014
- 2014-10-17 MX MX2016004736A patent/MX377714B/es active IP Right Grant
- 2014-10-17 EP EP14792686.9A patent/EP3057990B1/en active Active
- 2014-10-17 EA EA201690633A patent/EA037890B1/ru unknown
- 2014-10-17 JP JP2016524116A patent/JP6607850B2/ja active Active
- 2014-10-17 CA CA2926853A patent/CA2926853C/en active Active
- 2014-10-17 KR KR1020167013164A patent/KR102338453B1/ko active Active
- 2014-10-17 AU AU2014337135A patent/AU2014337135B2/en active Active
- 2014-10-17 US US15/026,460 patent/US9968674B2/en active Active
- 2014-10-17 WO PCT/US2014/061071 patent/WO2015058048A1/en not_active Ceased
- 2014-10-17 CN CN201480054902.1A patent/CN105636986B/zh active Active
-
2016
- 2016-03-15 IL IL24459916A patent/IL244599B/en active IP Right Grant
-
2018
- 2018-04-23 US US15/959,595 patent/US10532096B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7170691B2 (ja) | 抗ｌａｇ３抗体およびその使用 | |
| TWI707871B (zh) | 抗lag3抗體 | |
| US20240190999A1 (en) | Multispecific proteins | |
| US9822181B2 (en) | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof | |
| JP7162535B2 (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP2020115876A (ja) | Ｐｄ−ｌ１に対するヒト抗体 | |
| JP2023062184A (ja) | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質 | |
| RS59688B1 (sr) | 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka | |
| JP2023145487A (ja) | 抗ｔｉｍ－３抗体のための投与レジメンおよびその使用 | |
| JP2016527286A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| EP3043819A1 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
| CN106068275A (zh) | 抗pd‑1的人抗体 | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2015529641A5 (enExample) | ||
| RU2012139829A (ru) | АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8 | |
| JP2014534237A5 (enExample) | ||
| JP2020530770A5 (enExample) | ||
| JP2015506961A5 (enExample) | ||
| CN110381974A (zh) | 基于csf1r的嵌合蛋白 | |
| CN108026159B9 (zh) | Btla融合蛋白激动剂及其用途 | |
| CN113454123A (zh) | Lilrb3结合分子及其用途 | |
| JP2024509501A (ja) | 新規活性を持つｈｈｌａ２結合剤 | |
| TW202328196A (zh) | 使用vista抗原結合分子的癌症之治療及預防 |